• Profile
Close

Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration

Acta Ophthalmologica Jul 16, 2019

Aurell S, et al. - In eyes with neovascular age-related macular degeneration (nAMD) treated with antivascular endothelial growth factor injections, researchers assessed treatment outcome at 12 months in relation to pro re nata (PRN)- or treat-and-extend (TE)-regimen, in one clinical setting in Sweden. Overall 443 eyes including 223 PRN- and 220 TE-treated eyes were included in this study. Findings revealed better visual outcome at 12 months in eyes treated according to TE. In clinical routine care of nAMD, the superiority of treatment according to proactive TE-regimen, compared with treatment according to PRN-regimen, is suggested.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay